menu
    • menu
    [{"orgOrder":0,"company":"Shanghai Bao Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"KJ101","moa":"CD47 | D2 receptor | PD-1","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Shanghai Bao Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Dressing","sponsorNew":"Shanghai Bao Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Bao Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Bao Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"KJ015","moa":"HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Bao Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Bao Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Bao Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Bao Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Hyaluronidase","moa":"Hyaluronic acid","graph1":"Undisclosed","graph2":"Phase III","graph3":"Shanghai Bao Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Bao Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Bao Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Bao Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"KJ103","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Shanghai Bao Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Bao Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Bao Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Bao Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"KJ103","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Shanghai Bao Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Bao Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Bao Pharmaceuticals \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Shanghai Bao Pharmaceuticals

    Menu

    Shanghai Bao Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Shanghai Bao Pharmaceuticals

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Shanghai Bao Pharmaceuticals

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KJ015

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Clinical Trail of KJ015 in Patients with HER2-Expressing Solid Tumors

                            Details : KJ015 is a Antibody drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Gastroesophageal Junction Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            June 25, 2025

                            Lead Product(s) : KJ015

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Shanghai Bao Pharmaceuticals

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Shanghai Bao Pharmaceuticals

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KJ101

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase II Clinical Trial of KJ101in the Treatment of Deep II Degree Burns

                            Details : KJ101 is a Antibody drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Burns.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            June 17, 2025

                            Lead Product(s) : KJ101

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Shanghai Bao Pharmaceuticals

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Shanghai Bao Pharmaceuticals

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KJ103

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Clinical Trial With KJ103 in Anti-GBM Disease

                            Details : KJ103 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Anti-Glomerular Basement Membrane Disease.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            September 23, 2024

                            Lead Product(s) : KJ103

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Shanghai Bao Pharmaceuticals

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Shanghai Bao Pharmaceuticals

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hyaluronidase

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Hyaluronidase Assisted Subcutaneous Infusion

                            Details : Hyaluronidase is a Enzyme drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            September 19, 2024

                            Lead Product(s) : Hyaluronidase

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Shanghai Bao Pharmaceuticals

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Shanghai Bao Pharmaceuticals

                            China arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KJ103

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate the Safety and Tolerability of KJ103 in Healthy Adults

                            Details : KJ103 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            March 10, 2022

                            Lead Product(s) : KJ103

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth